Free tool
FAERS Monitor: Temodar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022277 or its brand name (Temodar, Temozolomide). Reports on generic versions are filed under their own applications.
Reports
21,320
Serious
17,250
81% of reports
Hospitalization
6,806
Death reported
4,502
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression1,895
- off label use1,833
- death1,811
- thrombocytopenia1,592
- product use in unapproved indication1,474
- nausea1,332
- drug ineffective1,270
- fatigue1,050
- neutropenia1,041
- vomiting991
- malignant neoplasm progression944
- febrile neutropenia839
- diarrhoea801
- anaemia765
- asthenia649
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 149 |
| 2005 | 291 |
| 2006 | 304 |
| 2007 | 579 |
| 2008 | 747 |
| 2009 | 441 |
| 2010 | 403 |
| 2011 | 462 |
| 2012 | 736 |
| 2013 | 671 |
| 2014 | 617 |
| 2015 | 779 |
| 2016 | 852 |
| 2017 | 1,041 |
| 2018 | 1,205 |
| 2019 | 1,170 |
| 2020 | 1,483 |
| 2021 | 1,560 |
| 2022 | 1,994 |
| 2023 | 1,746 |
| 2024 | 1,527 |
| 2025 | 1,524 |
| 2026 | 1,039 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,839 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 1,895 | 16.0 | 15.4 | 26,431 |
| thrombocytopeniaSignal | 1,592 | 14.2 | 13.6 | 19,398 |
| febrile neutropeniaSignal | 839 | 12.6 | 11.8 | 8,884 |
| malignant neoplasm progressionSignal | 944 | 9.2 | 8.6 | 6,832 |
| neutropeniaSignal | 1,041 | 7.6 | 7.2 | 5,957 |
| product use in unapproved indicationSignal | 1,474 | 5.9 | 5.6 | 6,024 |
| anaemiaSignal | 765 | 4.0 | 3.7 | 1,705 |
| vomitingSignal | 991 | 2.1 | 2.0 | 567 |
| deathSignal | 1,811 | 2.1 | 2.0 | 1,050 |
| off label useSignal | 1,833 | 2.1 | 2.0 | 1,051 |
| asthenia | 649 | 1.7 | 1.6 | 191 |
| nausea | 1,332 | 1.7 | 1.6 | 363 |
| fatigue | 1,050 | 1.3 | 1.3 | 89 |
| diarrhoea | 801 | 1.2 | 1.1 | 34 |
| drug ineffective | 1,270 | 1.0 | 0.9 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.